Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Burkitt Lymphoma 2Recurrence 1Neoplasm, Residual 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Biphenotypic, Acute 1Leukemia 1

Interventions

Cyclophosphamide 21Cytarabine 15blinatumomab 13fludarabine 12Azacitidine 10venetoclax 9fludarabine phosphate 9Blood Specimen Collection 8Methotrexate 7Lenalidomide 7Dexamethasone 7Rituximab 6Mercaptopurine 6Daunorubicin 6Vincristine 5daratumumab 4Whole-Body Irradiation 4Melphalan 4Etoposide 4Busulfan 4obinutuzumab 3Radiotherapy 3Neoadjuvant Therapy 3Maintenance 3Liquid Biopsy 3Immunotherapy, Adoptive 3Idarubicin 3Granulocyte Colony-Stimulating Factor 3Drug Therapy 3Doxorubicin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neoplasm, Residual × tisagenlecleucel × Clear all
NCT02529813 2022-06-30

CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies

M.D. Anderson Cancer Center

Phase 1 Completed
26 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡